A Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with auricular transcutaneous vagus nerve stimulation (aTVNS).
Eligibility criteria
Qualifiers
Age 18-75, Persistent Postural-Perceptual Dizziness (PPPD) diagnosis per International Classification of Vestibular Disorders (ICVD).
Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in.
On stable medications/therapy for ≥4 weeks prior to baseline (if any).
Disqualifiers
Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia.
Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (>1 in past 12 months).
Neck surgery, vagotomy, or any condition interfering with vagal stimulation.
Pregnancy.
Trial design
Treatments tested in this trial
- Sham Device
- Auricular transcutaneous vagus nerve stimulation
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov